New use urged for Amgen drug
- Share via
From Times Wire Services
A U.S. advisory panel unanimously urged regulators to approve an Amgen Inc. drug for a rare blood disorder that puts patients at risk of bleeding.
The Food and Drug Administration advisors said the benefits of Nplate outweighed the risks for treating chronic immune thrombocytopenia purpura.
The FDA usually follows the panel’s recommendations. Thousand Oaks-based Amgen said it expected a final ruling in the first half of this year.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
